In murine models of HCC, the combination of VEGF inhibition and PD-1 blockade leads to increased intratumoral CD8+ T cell infiltration and more pronounced tumor regression than either therapy alone [48–50]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.